Filtered By:
Therapy: Palliative

This page shows you your search results in order of date.

Order by Relevance | Date

Total 5 results found since Jan 2013.

Decreased IL-6 induces sensitivity of hepatocellular carcinoma cells to sorafenib
Publication date: Available online 25 July 2019Source: Pathology - Research and PracticeAuthor(s): Jing Yang, Jiali Wang, Jialin LuoAbstractSorafenib has been recommended as a new palliative therapy for advanced hepatocellular carcinoma (HCC). However, the sensitivity of HCC cells to sorafenib is declined along with the extension of medication time, and the clinical outcome varies with patients receiving sorafenib therapy. Therefore, in the present study, we attempted to investigate the effect and mechanisms of IL-6 on sensitivity of HCC cells to sorafenib regarding the cell proliferation and apoptosis. Tissues from patien...
Source: Pathology Research and Practice - July 25, 2019 Category: Pathology Source Type: research

Abstract B08: ER chaperone GRP78 increases chemoresistance in pancreatic ductal adenocarcinoma
Conclusions: Collectively, our data show that GRP78 expression promotes chemoresistance in PDAC and therapeutic strategies blocking the activity of GRP78 increase the efficacy of currently available therapies.Citation Format: Jenifer B. Gifford, Wei Huang, Ann E. Zeleniak, Antreas Hindoyan, Hong Wu, Timothy R. Donahue, Reginald Hill.{Authors}. ER chaperone GRP78 increases chemoresistance in pancreatic ductal adenocarcinoma. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2016 May 12-15; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2016;76(24 Suppl):Abstract nr B08.
Source: Cancer Research - December 13, 2016 Category: Cancer & Oncology Authors: Jenifer B. Gifford, Wei Huang, Ann E. Zeleniak, Antreas Hindoyan, Hong Wu, Timothy R. Donahue, Reginald Hill Tags: Molecular Drivers of Pancreatic Cancer Biology and Metastasis Source Type: research

Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy.
We describe the safety and toxicity studies with siG12D-LODER in 192 Hsd:Sprague Dawley rats, after repeated subcutaneous administrations (days 1, 14, and 28). Animals were sacrificed on days 29 and 42 (recovery phase). In all groups, no adverse effects were noted, and all animals showed favorable local and systemic tolerability. Histopathologically, LODER implantation resulted in the expected capsule formation, composed of a thin fibrotic tissue. On the interface between the cavity and the capsule, a single layer composed of macrophages and multinucleated giant cells was observed. No difference was noted between the place...
Source: Toxicologic Pathology - May 3, 2016 Category: Pathology Authors: Ramot Y, Rotkopf S, Gabai RM, Khvalevsky EZ, Muravnik S, Marzoli GA, Domb AJ, Shemi A, Nyska A Tags: Toxicol Pathol Source Type: research

Systemic PSMA-Targeted IR Sensitization
Radiation therapy is a highly effective tool for treating all stages of prostate cancer, from curative approaches in localized disease to palliative care and enhanced survival for patients with distant bone metastases. The therapeutic index of these approaches may be enhanced with targeted radiation-sensitizing agents. Aptamers are promising nucleic acid delivery agents for short interfering RNAs (siRNA) and short hairpin RNAs (shRNA). We have previously developed a radiation-sensitizing RNA aptamer–shRNA chimera that selectively delivers DNA-PK targeting shRNAs to prostate-specific membrane antigen (PSMA) positive c...
Source: Molecular Cancer Therapeutics - December 6, 2015 Category: Cancer & Oncology Authors: Ni, X., Zhang, Y., Zennami, K., Castanares, M., Mukherjee, A., Raval, R. R., Zhou, H., DeWeese, T. L., Lupold, S. E. Tags: Large Molecule Therapeutics Source Type: research

Abstract 2273: c-Rel is a critical mediator of NF-{kappa}B-dependent apoptosis resistance of pancreatic cancer cells against TRAIL
In conclusion, c-Rel is a critical mediator of NF-κB dependent anti-apoptotic signalling in PDAC through activation of NFATc2 and COX-2. Citation Format: Claudia Geismann, Frauke Grohmann, Gabriele Wirths, Susanne Sebens, Anita Dreher, Robert Häsler, Sebastian Zeissig, Stefan Schreiber, Philip Rosenstiel, Heiner Schäfer, Alexander Arlt. c-Rel is a critical mediator of NF-κB-dependent apoptosis resistance of pancreatic cancer cells against TRAIL. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;7...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Geismann, C., Grohmann, F., Wirths, G., Sebens, S., Dreher, A., Hasler, R., Zeissig, S., Schreiber, S., Rosenstiel, P., Schafer, H., Arlt, A. Tags: Molecular and Cellular Biology Source Type: research